📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years' experience at a UK high-secure hospital. (2022)

First Author: Attard A

Attributed to: PsySTAR Programme (Psychiatry: Scottish Training in Academic Research Programme) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/20451253221113093

PubMed Identifier: 35874556

Publication URI: http://europepmc.org/abstract/MED/35874556

Type: Journal Article/Review

Volume: 12

Parent Publication: Therapeutic advances in psychopharmacology

ISSN: 2045-1253